Home Press Center Press Releases  Press Release

Press Releases

New Data From European Screening Trial Supports Prostate Cancer Testing
Rotterdam data demonstrates significant difference in mortality in favor of screening

SAN DIEGO, CA, May 3, 2013—Prostate cancer screening can reduce the risk of dying from prostate cancer for men ages 55-69 by 28 percent, according to data from the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Researchers from the Erasmus University Medical Centre in the Netherlands presented the data today at the 2013 Annual Meeting of the American Urological Association in San Diego, CA.

The 42,376 men ages 55 to 74 were randomized to either a screening arm (n=21,210) or a control (n=21,166) arm. Men randomized to the group being offered screening were tested using prostate-specific antigen (PSA) every two or four years with an average follow-up of 12.8 years. The cut-off value for deciding if further investigation was needed was set at a PSA level of 3.0 ng/mL or more. Data analyses from the study revealed:

  • Overall risk reduction for death from prostate cancer in men who were screened was 16 percent.
  • Relative risk reduction for death from prostate cancer in those 55-69 years of age was 28 percent.
  • No benefit was demonstrated for those 70 to 74 years of age.

“The ERSPC randomized controlled trial clearly shows PSA screening can decrease deaths from prostate cancer in men ages 55 to 69,” said Scott Eggener, MD, Associate Professor, Urologic Oncology, University of Chicago. “Considering prostate cancer is the second-leading cause of cancer death in men, PSA-based prostate cancer screening, should be discussed between a man and his physician, especially for men age 55-69.”

The ERSPC is one of the longest-running randomized studies of prostate cancer screening in the world and includes 184,000 participants in eight countries, including Belgium, Finland, France, Italy, Netherlands, Spain, Sweden and Switzerland. In 2009, the study was unblended, allowing for reporting of end-point related results from individual study centers.

NOTE TO REPORTERS: Experts are available to discuss these studies. To arrange an interview with an expert, please contact the AUA Communications Office at the number above or e-mail

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 19,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.

Christine Frey, AUA